A detailed history of State Street Corp transactions in Arca Biopharma, Inc. stock. As of the latest transaction made, State Street Corp holds 59,707 shares of ABIO stock, worth $213,153. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,707
Previous 71,137 16.07%
Holding current value
$213,153
Previous $120,000 12.5%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.58 - $1.78 $18,059 - $20,345
-11,430 Reduced 16.07%
59,707 $105,000
Q3 2023

Nov 14, 2023

SELL
$2.01 - $2.07 $1,004 - $1,035
-500 Reduced 0.7%
71,137 $142,000
Q2 2022

Aug 15, 2022

BUY
$2.2 - $2.53 $3,740 - $4,301
1,700 Added 2.43%
71,637 $178,000
Q3 2021

Nov 15, 2021

BUY
$2.77 - $3.74 $2,493 - $3,366
900 Added 1.3%
69,937 $207,000
Q2 2021

Aug 16, 2021

BUY
$3.06 - $3.9 $211,253 - $269,244
69,037 New
69,037 $241,000

Others Institutions Holding ABIO

About ARCA biopharma, Inc.


  • Ticker ABIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,410,100
  • Market Cap $51.4M
  • Description
  • ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydr...
More about ABIO
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.